Eupraxia Pharmaceuticals (EPRX) Payables (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Payables of $7.2 million for Q1 2026, up 233.4% year-over-year from $2.1 million in Q1 2025, and up 29.0% quarter-over-quarter from $5.5 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Payables (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Payables for 5 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 233.4% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $7.2 million (up 233.4% YoY), while the FY2025 annual figure was $5.5 million, up 83.06% from the prior year.
- Payables improved to $7.2 million in Q1 2026 per EPRX's latest filing, from $5.5 million in the prior quarter.
- Across five years, Payables topped out at $7.2 million in Q1 2026 and bottomed at $2.0 million in Q2 2024.
- Historically, Payables has averaged $3.6 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2025 — Payables plunged 45.94% — and 2026, when it jumped 233.4%.
- Eupraxia Pharmaceuticals' Payables stood at $2.9 million in 2022, then soared by 33.92% to $3.9 million in 2023, then slipped by 22.7% to $3.0 million in 2024, then surged by 83.06% to $5.5 million in 2025, then climbed by 29.0% to $7.2 million in 2026.
- Business Quant data shows EPRX's Payables at $7.2 million in Q1 2026, $5.5 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 7.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.16 Mn |
| Dec 31, 2025 | 5.55 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 2.58 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 3.97 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Dec 31, 2022 | 2.93 Mn |